Skip to Content

No difference on survival for patients with metastatic castration-resistant prostate cancer treated with apalutamide-abiraterone combination therapy

Prolonged radiologically progression-free survival did not transfer into better overall survival in men with metastatic castration-resistant prostate cancer (mCRPC) treated with two androgen-targeted drugs instead of one.

Få tilgang til artikkelen

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Back to top